New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

Prespecified subgroup analyses showed that primary surgery conferred greater benefits for patients with stage III disease and ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

Five early-career Fred Hutch/UW researchers received prestigious Young Investigator Awards from Conquer Cancer, the ASCO Foundation during this year's annual meeting of the American Society of ...

New research presented at the 2025 American Society for Clinical Oncology’s (ASCO) annual meeting has shed light on the ...

Abstracts published ahead of the 2025 American Society of Clinical Oncology Annual Meeting found persistent ovarian cancer survival disparities among racial and ethnic subgroups, particularly ...

Alphamab Oncology (stock code: 9966.HK) announced that multiple clinical data updates for anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 were presented as posters at the 2025 Annual ...

The data were featured during an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025, in Chicago and online. "GBM represents ...

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Harbinger Health has reported clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, ...